Neurocrine Biosciences (NBIX) Asset Utilization Ratio (2011 - 2026)

Neurocrine Biosciences has reported Asset Utilization Ratio for 16 years, with the latest figure at 0.65 in Q1 2026.

• For the quarter ending Q1 2026, Asset Utilization Ratio changed 0.14% year-over-year to 0.65; the trailing twelve-month figure through Mar 2026 stood at 0.65 (changed 0.14% YoY), and the FY2025 full-year result was 0.69, up 1.38% from the prior year.
• Asset Utilization Ratio for Q1 2026 stood at 0.65, up from 0.64 in the prior quarter.
• The five-year high for Asset Utilization Ratio was 0.67 in Q2 2023, with the low at 0.45 in Q2 2022.
• Historically, Asset Utilization Ratio has averaged 0.6 across 5 years, with a median of 0.64 in 2025.
• Annual changes were most pronounced in 2022 — Asset Utilization Ratio fell 16.66% — and 2023, when it soared 48.76%.
• Neurocrine Biosciences' Asset Utilization Ratio stood at 0.5 in 2022, then increased by 23.48% to 0.62 in 2023, then advanced by 4.95% to 0.65 in 2024, then fell by 0.98% to 0.64 in 2025, then increased by 1.17% to 0.65 in 2026.
• The last three Asset Utilization Ratio figures came in at 0.65 (Q1 2026), 0.64 (Q4 2025), and 0.66 (Q3 2025), per Business Quant data.